We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Endo Petitions FDA to Keep Opana Control as More ANDAs Are Submitted
Endo Petitions FDA to Keep Opana Control as More ANDAs Are Submitted
October 5, 2012
Endo Pharmaceuticals is petitioning the FDA to require generics referencing its crush-resistant pain drug, Opana ER CRF, demonstrate they are similarly crush-resistant.